SEC Form 4 · accession 0001209191-15-067187

GYRE THERAPEUTICS, INC. · GYRE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 20, 2015

Accepted (ET)

Aug 20, 2015 · 6:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001124105

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Aug 20, 2015	J	16,232	—	A	16,232	D
Common Stock^F1	Aug 20, 2015	J	382	—	A	16,614	I	By Spouse

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F2	$10.48	Aug 20, 2015	J	2,966	A	—	May 13, 2020	Common Stock	2,966	2,966	D
Warrant (Right to Buy)^F3	$33.27	Aug 20, 2015	J	287	A	—	Apr 9, 2019	Common Stock	287	287	D

F1Represents shares of the Issuer issued pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 5, 2015 as amended on May 6 and May 13, 2015, by and among the Issuer, Talos Merger Sub, Inc. and a Delaware corporation then known as Catalyst Biosciences, Inc. ("Old Catalyst"). Pursuant to the terms of the Merger Agreement, each share of common stock of Old Catalyst was converted into 0.0382 shares of the Issuer's common stock.
F2On May 13, 2010, Reporting Person was granted an option to purchase 77,652 shares of the common stock of Old Catalyst under Old Catalyst's 2004 Stock Plan at an exercise price of $0.40 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 2,966 shares of the Catalyst's common stock at a per share exercise price of $10.48. The option is fully vested and exercisable.
F3On April 9, 2014, Reporting Person acquired a warrant to purchase 7,532 shares of the Series E Preferred Stock of Old Catalyst at an exercise price of $1.2706 per share. Each share of Series E Preferred Stock of Old Catalyst was convertible into 1 share of common stock of Old Catalyst. Pursuant to the Merger Agreement, this warrant was converted into a warrant to purchase 287 shares of the Catalyst's common stock at a per share exercise price of $33.27. The warrant is fully vested and exercisable.